Zorubicin
![]() | |
| Clinical data | |
|---|---|
| Trade names | rubidazon, rubidazone |
| Routes of administration | i.v. |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C34H35N3O10 |
| Molar mass | 645.665 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Zorubicin (INN) is a benzoylhydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin. Zorubicin intercalates into DNA; it as well interacts with topoisomerase II and inhibits DNA polymerases and therefore is used to treat cancer.[1][2]
References
- ^ "NCATS Inxight Drugs — ZORUBICIN". drugs.ncats.io.
- ^ Li X, Xu S, Tan Y, Chen J (June 2015). "The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia". The Cochrane Database of Systematic Reviews. 2015 (6): CD010432. doi:10.1002/14651858.CD010432.pub2. PMC 11218035. PMID 26037486.
